Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Appoints Strategic Advisor, Advances Tech Platform as Alternative to Smoking and Vaping

  • Lexaria Bioscience is dedicated to providing healthful alternatives to drug-substance inhalation by providing an edible technology that works as effectively as smoking or vaping at getting substances into the bloodstream
  • The company’s DehydraTECH platform has been licensed to multiple companies in the cannabis and tobacco industries, and Canada’s recent nationwide legalization of cannabis edibles is expected to open even more of a market
  • Gregg Smith, the founder of a New York-based “culture tech” venture investment firm, has joined Lexaria as a senior advisor to help define the company’s leadership strategies

Innovations in drug delivery are making the wellness product market safer and more effective in its niche as an alternative to costly pharmaceuticals or foreign remedies that lack governmental approval. Bio-delivery technology developer Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a world leader in edible drug science to combat the ills of substances that might otherwise be inhaled into the lungs.

Lexaria’s proprietary DehydraTECH™ drug delivery platform is patented to work with existing substances such as nicotine, cannabidiol (CBD) and other non-psychoactive and psychoactive cannabinoids to get…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) DehydraTECH Drug-Delivery Platform May Ease Overdose Risk in Cannabis Edibles

  • Edible cannabis products are absorbed slowly
  • Consumers of cannabis edibles often mistake the delayed effect for insufficiency, leading to overdosing
  • DehydraTECH drug-delivery platform speeds up absorption, reducing overdose risk

Sometimes what is gained on the roundabouts is lost on the swings, to paraphrase an old saying. Cannabis liberalization has introduced an entirely new sector to the food and beverage industry – namely, cannabis edibles such as cookies, chocolates and candies. It’s a sector that appears poised for growth. But as mass consumption increases, a hidden problem is emerging (http://cnw.fm/JwQv3). Because bioabsorption rates via edibles are slower than those via smoking, oral ingestion is leading to unexpected challenges. Consumers mistake the slow onset of effect of traditional cannabis edibles for not enough cannabinoid, so they increase consumption which can lead to overdosing. However, a biotech solution from Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) appears to solve this problem. The company’s DehydraTECH(TM) drug-delivery platform greatly increases the rate at which drugs like cannabis are absorbed by the body. The technology could be used to avoid overdoses before they ever begin.

Consumers have certainly developed a taste for cannabis. A recent report projects the global cannabis-edibles market will reach over $11.6 billion by 2025, climbing at a CAGR of 25 percent, from $2.4 billion in…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Makes Strides with Patented DehydraTECH™ Drug Delivery Platform

  • Lexaria Bioscience Corp. continues to make progress in the patenting and development of its DehydraTECH™ platform
  • Lexaria developed the patented DehydraTECH™ drug delivery platform as a safer alternative to inhalation of nicotine or cannabinoids
  • DehydraTECH™ has been shown to facilitate rapid uptake and highly targeted delivery of pharmaceuticals to the brain

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has levered innovation, research and development into operations in four market verticals: cannabis, hemp, nicotine, and pharmaceuticals. Lexaria already introduced the DehydraTECH™ drug delivery platform into commercial use and has a second-generation delivery platform ready for launch in 2020. Lexaria is the only company in the world to receive a patent for this improved oral delivery of all non-psychoactive cannabinoids including CBD. In fact, the company has 16 patents already granted along with more than 60 patents that are pending worldwide (http://cnw.fm/Bnsc5).

Lexaria has cannabinoid licensing agreements with various companies in North America. The popularity of cannabinoid products such as CBD is likely to increase in the future and the U.S. cannabis market alone is projected to grow substantially in…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Advances Innovation Research Through Agreement with Altria

  • The program focuses on the pursuit of reduced risk oral nicotine products that make use of Lexaria’s patented DehydraTECH drug delivery platform
  • DehydraTECH has been studied extensively and both human/animal trials confirm its ability to enhance active ingredient absorption in digestible products
  • The current research could contribute to the development of oral nicotine products that would usher in a new era of reduced-risk nicotine use

Global innovator in drug delivery platforms Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) provided an extensive update on advances in its research and development program with Altria Ventures Inc., an indirect wholly owned subsidiary of Altria Group, Inc (NYSE: MO). The collaboration focuses on the pursuit of reduced risk oral nicotine consumer products using the Lexaria-patented DehydraTECH technology.

Most of the work within the first phase of the collaborative project has either been completed or is significantly underway. Only one aspect of the project remains to commence imminently, according to a company press release issued on…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Sees Ever-Expanding Customer Base for DehydraTECH Drug Delivery Platform

  • Lexaria Bioscience recently announced its DehydraTECH(TM) patent for pharmaceutical applications of cannabinoids to treat certain disease conditions
  • Lexaria Bioscience’s patented DehydraTECH drug delivery platform can be used to deliver nicotine, cannabinoids and many other useful substances
  • The company has roughly 60 patents pending in countries around the world for its DehydraTECH drug delivery platform

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is at the forefront of the development of useful biotechnology products and has played a pivotal role in developing a way to deliver substances to the brain via non-inhalation methods through the development of a novel drug delivery platform.

The DehydraTECH drug delivery platform was developed by Lexaria Bioscience Corp. and has already received patents in both the United States and Australia, most recently for pharmaceutical applications of cannabinoids to treat certain disease conditions…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Rolls Out Online Sales of Discrete Powdered Formulation of CBD-Rich Hemp Oil

  • Lexaria Bioscience is an innovator in the field of bioavailable lipophilic active compounds, and it is working to make consumption of certain products through oral ingestion a viable alternative to inhalation
  • A particular focus of the company’s technology is to ensure that cannabinoids can enter the blood stream at speeds comparable to smoking and can be used in a discrete manner
  • Cannabis-infused beverage sales are expected to surpass $1.4 billion by 2024, marking a nearly 15-fold increase over 2018 levels

Drug bio-delivery technology innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has launched online commercial delivery of the cannabis industry’s most advanced water-soluble multi-spectrum hemp oil in a powdered format, making high-quality hemp oil with cannabidiol (CBD) readily available to meet the beverage infusion needs of consumers in the United States.

The company’s August 22 announcement (http://cnw.fm/a3Kr5) states that its ChrgD+ product is powered by Lexaria’s proprietary DehydraTECH(TM) technology for rapid CBD delivery to the user’s bloodstream within…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

420 with CNW – What is CBD, and what is its Relationship with THC?

People who have heard about CBD-infused drinks, cosmetics and pet food may be wondering why that cannabis extract isn’t attracting as much polarized attention as THC. Read on and learn everything that you need to know about CBD and THC, and why CBD is gaining in popularity in nearly every industry.

A Brief Primer on Cannabinoids…

The cannabis plant has more than 100 different compounds within it. These are called cannabinoids and terpenes, so you should therefore not imagine that the cannabis plant has only two compounds. However, two of the most abundant cannabinoids in the cannabis plant are CBD (cannabidiol) and THC (tetrahydrocannabinol).

THC is the psychoactive cannabinoid that makes cannabis consumers “high” while CBD isn’t psychoactive.

Marijuana vs. Hemp?

Cannabis is a general term used to refer to a family of plants that have similar compounds (cannabinoids). Marijuana and hemp are therefore members of the same family.

However, hemp has a very small amount of THC in it. The U.S. federal government describes a given plant in the cannabis family as hemp if that plant has less than 0.3 percent concentration of THC. By the same token, marijuana is the other member of the cannabis family that has THC levels that are higher than the threshold for the hemp plant.

Remember, “hemp” and “marijuana” are arbitrary terms given to the same plant only that the level of THC determines which of those two words you will use to refer to the plant you are looking at.

Why is CBD Readily Available Yet Marijuana is Illegal?

As already mentioned, CBD is one of the non-psychoactive compounds found in the cannabis plant. This cannabinoid has several medicinal properties, such as anxiety, pain and insomnia relief.

Recently, President Trump signed into law the Farm Bill of 2018 and this law changed the legal status of hemp to an agricultural product (just like soy, corn or any other plant). Consequently, extracting CBD oil from hemp doesn’t break any U.S. law.

In contrast, marijuana is a Schedule 1 controlled substance that is illegal at the federal level. However, dozens of states have legalized medical marijuana and nearly a dozen have legalized adult-use marijuana.

The laws and attitudes surrounding marijuana haven’t affected the reputation of CBD and that is why it is widely available.

Do Consumers of CBD Face Any Safety Risks?

Interestingly, nearly all the literature available on CBD says that it is safe for consumption. However, little is known about how this compound may interact with other substances, such as conventional medications, in the body.

Additionally, CBD extracts haven’t been used for a long enough time to assess their effects on pregnant women and their unborn babies. Caution is therefore recommended for people in high-risk categories (expectant mothers and babies, for example).

As you can see, CBD seems set to continue on its forward march now that hemp is an agricultural product that can be widely cultivated for various purposes. Cannabis industry players like Marijuana Company of America, Inc. (OTCQB: MCOA) and Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) would like to see a time when marijuana is accepted the way hemp is now accepted.

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

Outside Investment, New Technology Support Growing Cannabis Industry

CannabisNewsWire Editorial Coverage: Revolutionary innovations and advancements within the cannabis industry are drawing significant investment from big corporations.

  • Technology currently in development will make it easier to consume active ingredients in cannabis.
  • Advances have attracted investment for the technology’s use in tobacco as well as cannabis.
  • These improvements could move consumers to healthier forms of consumption than smoking.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) (LXRP Profile) has benefited from recent investment by Altria to support its innovative research and design work. Canopy Growth Corporation (NYSE: CGC) (TSX: WEED) has received substantial investment from a beverage company, which will support the development of cannabis drinks. Within the sector, Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB) is in the process of acquiring an organic grower. Outside investment is bolstering Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON), a cannabis company with global reach. And another innovator, GW Pharmaceuticals Plc (NASDAQ: GWPH) (OTC: GWPRF), has run successful trials on…

Read More >>

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

420 with CNW – Oklahoma City School Board Passes Marijuana Policy

Voters in Oklahoma approved a ballot measure last year in June making medical marijuana legal in the state. Recently, the school district in Oklahoma City passed its own medical marijuana policy to clarify what employees and students could or could not do now that medical marijuana is legal in the state.

On Monday this week (January 14), the Oklahoma City Public Schools Board released its marijuana policy in which the district asserted that it would not take any action against any employee who holds a medical marijuana license.

However, the same policy also had a clause that barred employees from possessing marijuana within school premises or during office hours even if such an employee is licensed to use medical marijuana.

The policy also stipulated that while students would be allowed to have access to, and consume medical marijuana, employees in the schools aren’t allowed to administer that marijuana to the students.

Instead, the policy states that a private location would be provided so that the caregiver of a student can administer the medical marijuana from that location. Caregivers would also be solely responsible for bringing the medical marijuana and taking it away after the student has used or consumed it.

The policy warns that disciplinary action would be taken against any student or employee who violates the school district’s marijuana policy.

Additionally, the policy states that the school district will be free to alter the policy if the federal funding of the district is jeopardized in any way by the marijuana policy or its implementation. Ultimately, the school district will adhere to any restrictions or instructions given by the federal government regarding medical marijuana.

These provisions in the policy show how large the shadow of the federal government hovering over the entire country is on matters of marijuana.

So far, more than 30,000 people have applied for medical marijuana licenses since August when residents were allowed to start applying for the cards. A patient whose application is approved has to pay $100 in order to receive their license from the Department of Health. People who are at least 18 years old are eligible to apply for a medical marijuana license if a doctor recommends them to apply for one.

The action taken by the school district is a step in the right direction because it clarifies what employees and students should expect if they want to consume medical marijuana. Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), Green Hygienics Holdings Inc. (OTCQB: GRYN) and the entire marijuana industry welcome the positive action taken by the Oklahoma City Public Schools Board.

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

420 with CNW – Ohio Residents Petition for More Medical Marijuana Qualifying Conditions

Toward the end of this month, a special committee will sit to assess the different petitions that Ohioans submitted calling for additional conditions to be included on the list of ailments for which one can obtain a medical cannabis card.

The meeting this month comes after the end of a window within which people could send in their requests for the conditions they want to see on the qualifying list for access to medical cannabis.

Medical marijuana became legal in 2016 and 21 qualifying conditions were listed in that law. However, the law also granted the Medical Marijuana Board permission to review that list and add more conditions once each year.

The sale of medical marijuana is scheduled to start sometime this month and already more than 4,000 residents have secured medical marijuana cards. According to estimates, three in 10 Ohioans could qualify for a medical marijuana card even if the list of qualifying conditions stays as it was when the enabling law was passed.

The window within which interested parties could submit their petitions for additions to the list of qualifying conditions started on Nov. 1 and ended at the stroke of midnight on December 31. By the close of the window, 110 petitions had been submitted.

Those 110 petitions are now with a committee of lawyers advising the medical board. The lawyers will select some conditions indicated in the petitions and submit their shortlist to a committee that will meet tomorrow (January 9).

That committee will decide which of the conditions on the shortlist can be forwarded to medical experts for additional review and benchmarking in other states where medical cannabis programs exist.

The experts will then report back to the committee so that a report is presented to the full Medical Marijuana Board for a final vote. The Medical Board should have made their final decision by June 30, 2019, so that the list of qualifying conditions can be updated thereafter.

Some of the conditions in the petitions received include insomnia, depression and anxiety. Others are opioid addiction, acne, fibromyalgia and chronic pain. However, it should be noted that some of the petitions mentioned conditions that already appear among the 21 qualifying conditions listed in the 2016 law.

Currently, 33 states plus the District of Columbia have legalized medical marijuana. That notwithstanding, cannabis remains a Schedule 1 substance under federal law, so it is hard for scientists to study the plant and its derivatives in this prohibitionist legal environment.

Nonetheless, there are signs that the stringent controls will ease up a bit because already, the FDA has licensed a drug derived from cannabis, and permission was granted to a group of researchers at UC San Diego to import cannabis capsules from Canada for research purposes. Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) and Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) hope that the environment will become conducive soon enough at the federal level so that the industry in the U.S. can grow based on the findings of scientific studies.

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com